Retatrutide
Backed by published Phase 2 randomized trials; additional Phase 3 results are reading out through 2026.
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
In a prespecified phase 2a sub-analysis of participants with obesity and metabolic dysfunction-associated steatotic liver disease, the authors reported dose-dependent relative reductions in liver fat content over 48 weeks compared with placebo.
View study ↗Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a phase 2 trial
In this randomised, placebo- and active-controlled phase 2 trial in adults with type 2 diabetes, the authors reported dose-dependent reductions in HbA1c and body weight over 24 weeks, with a gastrointestinal adverse-event profile consistent with incretin-based agents.
View study ↗Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
In this randomised, double-blind, placebo-controlled phase 2 trial in adults with obesity, the authors reported dose-dependent mean body-weight reductions over 48 weeks compared with placebo, with mostly mild-to-moderate gastrointestinal adverse events.
View study ↗Provided for educational and reference purposes only. These materials are sold strictly for laboratory research and are not for human or animal use.